Floxibac 100 mg/ml Solution for Injection for Cattle and Pigs Irlanda - inglés - HPRA (Health Products Regulatory Authority)

floxibac 100 mg/ml solution for injection for cattle and pigs

chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 100 milligram(s)/millilitre - enrofloxacin - bovine, porcine - antibacterial

FLOXIBAC 100 MG/ML SOLUTION FOR INJECTION FOR CATTLE AND PIGS Irlanda - inglés - HPRA (Health Products Regulatory Authority)

floxibac 100 mg/ml solution for injection for cattle and pigs

chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 100 mg/ml - enrofloxacin - bovine, porcine - antibacterial

Floxibac 100 mg/ml Solution for Injection for Cattle and Pigs Reino Unido - inglés - VMD (Veterinary Medicines Directorate)

floxibac 100 mg/ml solution for injection for cattle and pigs

chanelle pharmaceuticals manufacturing ltd - enrofloxacin -

Floxibac 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats Irlanda - inglés - HPRA (Health Products Regulatory Authority)

floxibac 50 mg/ml solution for injection for cattle, pigs, dogs and cats

chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 50 milligram(s)/millilitre - enrofloxacin - bovine, canine, feline, porcine - antibacterial

FLOXIBAC 50 MG/ML SOLUTION FOR INJECTION FOR CATTLE, PIGS, DOGS AND CATS Irlanda - inglés - HPRA (Health Products Regulatory Authority)

floxibac 50 mg/ml solution for injection for cattle, pigs, dogs and cats

chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 50 mg/ml - enrofloxacin - bovine, canine, feline, porcine - antibacterial

Floxibac 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats Reino Unido - inglés - VMD (Veterinary Medicines Directorate)

floxibac 50 mg/ml solution for injection for cattle, pigs, dogs and cats

chanelle pharmaceuticals manufacturing ltd - enrofloxacin -

OFLOXIBACT 10 OZ India - inglés - Central Drugs Standard Control Organization

ofloxibact 10 oz

unisearch hc. - ofloxacin,ornidazole - oz - 250,500;mg - 10

OFLOXIBACT 10 TAB India - inglés - Central Drugs Standard Control Organization

ofloxibact 10 tab

unisearch hc. - ofloxacin - tab - 200mg - 10

AVELOX IV 400 moxifloxacin 400 mg/250 mL (as hydrochloride) intravenous infusion solution bottle Australia - inglés - Department of Health (Therapeutic Goods Administration)

avelox iv 400 moxifloxacin 400 mg/250 ml (as hydrochloride) intravenous infusion solution bottle

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

AVELOX IV 400 moxifloxacin 400 mg/250 mL (as hydrochloride) intravenous infusion solution bag Australia - inglés - Department of Health (Therapeutic Goods Administration)

avelox iv 400 moxifloxacin 400 mg/250 ml (as hydrochloride) intravenous infusion solution bag

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.